Page last updated: 2024-11-08

azd2563

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

posizolid: an antitubercular agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID213049
CHEMBL ID131854
SCHEMBL ID374786
MeSH IDM0422632

Synonyms (27)

Synonym
azd2563
CHEMBL131854
posizolid
azd-5847
azd-2563
252260-02-9
(5r)-3-[4-[1-[(2s)-2,3-dihydroxypropanoyl]-3,6-dihydro-2h-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one
azd5847
posizolid [inn:ban]
azd 5847
82v2m8k24r ,
(5r)-3-(4-(1-((2s)-2,3-dihydroxypropanoyl)-1,2,3,6-tetrahydro-4-pyridyl)-3,5-difluorophenyl)-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one
azd 2563
unii-82v2m8k24r
(5r)-3-(4-(1-((2s)-2,3-dihydroxypropanoyl)-1,2,3,6-tetrahydro-4-pyridyl)-3,5-difluorophenyl)-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolan-2-one
posizolid [inn]
posizolid [who-dd]
DB04850
(5r)-3-[4-[1-[(2s)-2,3-dihydroxypropanoyl]-3,6-dihydro-2h-pyridin-4-yl]-3,5-difluoro-phenyl]-5-(isoxazol-3-yloxymethyl)oxazolidin-2-one
SCHEMBL374786
gtpl12762
Q7233326
2-oxazolidinone, 3-[4-[1-[(2s)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-[(3-isoxazolyloxy)methyl]-, (5r)-
DTXSID40870284
CS-0010094
HY-15993
AKOS040753599

Research Excerpts

Overview

AZD2563 is a new, long-acting oxazolidinone that possesses potent antimicrobial activity against Gram-positive organisms.

ExcerptReferenceRelevance
"AZD2563 is a new oxazolidinone that has targeted activity against Gram-positive bacteria. "( In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
Fluit, AC; Milatovic, D; Schmitz, FJ; Verhoef, J, 2002
)
2.08
"AZD2563 is a new, long-acting oxazolidinone that possesses potent antimicrobial activity against Gram-positive organisms. "( Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone.
Anderegg, TR; Jones, RN, 2003
)
1.99
"AZD2563 is a novel oxazolidinone that has activity similar to linezolid and the potential for extended dosing intervals."( Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.
Anderegg, TR; Jones, RN, 2004
)
1.3

Compound-Compound Interactions

ExcerptReferenceRelevance
" When combined with gentamicin (MIC/4 concentration), rapid bactericidal action was observed against all streptococci tested, but not against the staphylococci."( AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.
Anderegg, TR; Deshpande, LM; Jones, RN, 2002
)
1.76

Dosage Studied

ExcerptRelevanceReference
" AZD2563 is a novel oxazolidinone that has activity similar to linezolid and the potential for extended dosing intervals."( Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.
Anderegg, TR; Jones, RN, 2004
)
1.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID207216In vitro minimum inhibitory concentration against Staphylococcus aureus Oxford2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.
AID209622In vitro minimum inhibitory concentration against Streptococcus pyogenes penicillin sensitive2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.
AID1432970Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay
AID1162166Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition2014European journal of medicinal chemistry, Oct-30, Volume: 86SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
AID1432971Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay
AID207215In vitro minimum inhibitory concentration against Staphylococcus aureus MRQR2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.
AID67565In vitro minimum inhibitory concentration against Enterococcus faecalis2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.
AID1432972Selectivity index, ratio of IC50 for African green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv
AID698837Bioavailability in human at 1200 mg2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID110692In vivo antibacterial activity against Staphylococcus aureus after intramuscular administration (5 mg/kg) in mice using (MTT) mouse thigh test2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.
AID110691In vivo antibacterial activity against Staphylococcus aureus after intramuscular administration (10 mg/kg) in mice using (MTT) mouse thigh test2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.
AID698840Bioavailability in human at 50 mg2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID207213In vitro minimum inhibitory concentration against coagulase negative Staphylococcus aureus methicillin resistant (CNSMR)2003Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (65.52)29.6817
2010's9 (31.03)24.3611
2020's1 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (17.24%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (82.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]